Lupin Limited’s Corporate Social Responsibility (CSR) arm announced today that it has signed a Memorandum of Understanding (MoU) with the Government of Maharashtra to address the growing prevalence of Cardiovascular Diseases (CVD) and Chronic Obstructive Pulmonary Disease (COPD) in Maharashtra’s Palghar district. The collaboration aims to emphasize disease identification and treatment while also striving to reduce their long-term prevalence.
Lupin has continuously advocated for increased access to high-quality, cost-effective medications for India’s underserved and vulnerable people as a premier healthcare provider. “Through our collaborative efforts with state governments, we hope to strengthen existing healthcare systems and programs, raise awareness, and improve the quality, accessibility, and utilization of healthcare services,” said Nilesh Gupta, Lupin’s Managing Director.
Dr. Nagnath Mudam, Joint Director (NCD), Directorate of Health Services, Maharashtra, and Tushara Shankar, Lupin’s Head of Corporate Social Responsibility, signed the MoU. This collaborative initiative is a critical milestone in LHWRF’s “Lives” agenda, highlighting the organization’s commitment to addressing the rising prevalence of cardiovascular illnesses and COPD.
This collaboration has the potential to drastically reduce the prevalence of CVDs and COPD in Palghar’s chosen blocks. Our unrelenting commitment to addressing these health issues with targeted solutions will have a long-term influence on the community.
We hope to alleviate the disease burden in the district by emphasizing preventive measures, early detection, and comprehensive treatment options, ultimately improving the community’s overall health and well-being,” said Dr. Nagnath Mudam, Joint Director (NCD), Directorate of Health Services, Maharashtra.
Tushara Shankar, LHWRF’s Head of Corporate Social Responsibility, stated, “Maharashtra has seen a significant increase in the prevalence of CVDs and COPD.” Our collaboration with the state government is centered on providing disease management healthcare services, facilitating supportive interventions, and emphasizing preventive measures. Our goal is to effectively treat these diseases and give holistic care to the affected population by providing a comprehensive solution.”
An evaluation study was done to map existing services, identify issues in healthcare delivery, and estimate cost-of-service gaps in order to create a solid basis. The Public Health Department (PHD) analyzed the findings and integrated them into Lupin’s final program.
The scheme will be phased in over the following five years, beginning with two blocks, Palghar and Dahanu. The key goals are to raise awareness about the dangers associated with CVDs and COPD, as well as to emphasize the significance of early screening and diagnosis in order to prevent complications and lower mortality rates. The campaign will also promote healthy lifestyles and preventive actions, emphasizing the importance of early screening, diagnosis, and treatment adherence.
More About LHWRF
Lupin Human Welfare & Research Foundation (LHWRF) is the social responsibility arm of Lupin limited, which has been working to positively impact rural landscapes since 1988. During its three-decade history, the foundation has touched over 5000 villages in 23 districts across nine states. The organization has been working to address all aspects of development for underprivileged communities in four thematic areas, namely Economic, Social, Infrastructure Development, and Natural Resource Management.
It undertakes economic development activities in the fields of agriculture, animal husbandry, women empowerment, and rural industries. The social anchors include health and education, while infrastructure development and natural resource development have been the key drivers of growth in backward regions where it operates. LHWRF has adopted a new strategic approach to working on Lives (Healthcare) and Livelihoods.
About Cardiovascular Diseases
Cardiovascular diseases refer to a group of disorders that affect the heart and blood vessels, including conditions such as coronary artery disease, heart failure, stroke, and hypertension. These diseases are a leading cause of death worldwide, posing a significant public health challenge. Risk factors for cardiovascular diseases include unhealthy lifestyle habits, such as smoking, poor diet, physical inactivity, obesity, and underlying medical conditions like diabetes and high cholesterol. Early detection, lifestyle modifications, and appropriate medical interventions play a crucial role in managing and preventing cardiovascular diseases.
More About Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.
Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
IR Research Publication is Publisher, Editorial, and Profile Building Service Provider. It Covers the Publication of Multiple Reputed Journals in the field of Biological, Medical, Pharmaceutical, and Life Sciences. IR Research Publication provides news on CDSCO decisions and FDA decisions, pharmaceutical industries, generic drugs, patents, and other pharma news.
For more details Click here